We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BFLY Stock Down Despite Launching Compass AI to Drive POCUS Programs
Read MoreHide Full Article
Key Takeaways
BFLY unveiled Compass AI to streamline and scale POCUS programs across health systems.
The platform targets workflow and documentation gaps to lift compliance.
Compass AI adds AI-based documentation, QA tools and integration features to improve revenue.
Butterfly Network, Inc. (BFLY - Free Report) recently introduced Compass AI, a next-generation enterprise software platform designed to streamline and scale point-of-care ultrasound (POCUS) programs across health systems. The company claims this shift can lift documentation compliance significantly and help health systems unlock more revenue from the same exam volume.
In the near term, Compass AI positions BFLY to benefit from stronger enterprise demand as health systems look for quick, revenue-enhancing solutions. The platform directly addresses long-standing workflow and compliance gaps, which could accelerate adoption and boost software-driven monetization.
Likely Trend of BFLY Stock Following the News
Following the announcement, the company's shares lost nearly 7% at yesterday’s closing. In the year-to-date period, shares have gained 34.7% against the industry’s 10.8% decline. The S&P 500 has gained 12.2% in the same time frame.
However, in the long run, Compass AI strengthens BFLY’s position as a core infrastructure partner for health systems, shifting the company toward a more durable, software-led revenue model. By embedding itself deeper into POCUS workflows and enterprise governance, BFLY can drive higher customer retention, expand multi-department deployments and steadily grow recurring revenue.
BFLY currently has a market capitalization of $535.5 million.
Image Source: Zacks Investment Research
More on the Launch
Butterfly Network’s Compass AI marks a significant upgrade to its enterprise platform, targeting longstanding workflow and documentation gaps in POCUS programs. Many health systems continue to rely on radiology-style, order-based processes that often lead to delayed documentation, missed orders and a high volume of exams going unreviewed or unreimbursed.
Traditional workflows capture only about 15% of compliant studies, leaving roughly 85% of exams unbilled. Compass AI introduces an AI-enhanced, encounter-based workflow built for POCUS, enabling documentation compliance rates of up to 94% without adding work for clinicians and helping health systems potentially generate up to five times more revenue from the same clinical load.
Compass AI brings together a full suite of AI-powered capabilities to support compliant and scalable POCUS operations. The Documentation Agent uses ambient voice dictation to complete exam notes automatically, reducing charting time by up to 25%. The QA Agent accelerates quality review through AI-based image evaluation and feedback.
The Program Dashboard tracks usage, documentation compliance, credentialing and unbilled studies, providing insights into operational performance and potential ROI. The platform also offers seamless integration with EHRs, PACS and SSO systems, ensuring studies are routed directly into the medical record and preventing lost images. Fleet Visibility enables oversight of users and devices, supporting broader governance across the health system.
With its ability to work across departments and ultrasound devices, Compass AI provides health systems with the visibility, governance and standardization needed to expand POCUS at scale. The platform supports improved documentation accuracy, stronger compliance, streamlined QA processes and enhanced revenue capture from exams that previously went unbilled. Butterfly Network confirmed that Compass AI is available starting today.
BFLY’s Zacks Rank & Key Picks
Currently, BFLY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BFLY Stock Down Despite Launching Compass AI to Drive POCUS Programs
Key Takeaways
Butterfly Network, Inc. (BFLY - Free Report) recently introduced Compass AI, a next-generation enterprise software platform designed to streamline and scale point-of-care ultrasound (POCUS) programs across health systems. The company claims this shift can lift documentation compliance significantly and help health systems unlock more revenue from the same exam volume.
In the near term, Compass AI positions BFLY to benefit from stronger enterprise demand as health systems look for quick, revenue-enhancing solutions. The platform directly addresses long-standing workflow and compliance gaps, which could accelerate adoption and boost software-driven monetization.
Likely Trend of BFLY Stock Following the News
Following the announcement, the company's shares lost nearly 7% at yesterday’s closing. In the year-to-date period, shares have gained 34.7% against the industry’s 10.8% decline. The S&P 500 has gained 12.2% in the same time frame.
However, in the long run, Compass AI strengthens BFLY’s position as a core infrastructure partner for health systems, shifting the company toward a more durable, software-led revenue model. By embedding itself deeper into POCUS workflows and enterprise governance, BFLY can drive higher customer retention, expand multi-department deployments and steadily grow recurring revenue.
BFLY currently has a market capitalization of $535.5 million.
Image Source: Zacks Investment Research
More on the Launch
Butterfly Network’s Compass AI marks a significant upgrade to its enterprise platform, targeting longstanding workflow and documentation gaps in POCUS programs. Many health systems continue to rely on radiology-style, order-based processes that often lead to delayed documentation, missed orders and a high volume of exams going unreviewed or unreimbursed.
Traditional workflows capture only about 15% of compliant studies, leaving roughly 85% of exams unbilled. Compass AI introduces an AI-enhanced, encounter-based workflow built for POCUS, enabling documentation compliance rates of up to 94% without adding work for clinicians and helping health systems potentially generate up to five times more revenue from the same clinical load.
Compass AI brings together a full suite of AI-powered capabilities to support compliant and scalable POCUS operations. The Documentation Agent uses ambient voice dictation to complete exam notes automatically, reducing charting time by up to 25%. The QA Agent accelerates quality review through AI-based image evaluation and feedback.
The Program Dashboard tracks usage, documentation compliance, credentialing and unbilled studies, providing insights into operational performance and potential ROI. The platform also offers seamless integration with EHRs, PACS and SSO systems, ensuring studies are routed directly into the medical record and preventing lost images. Fleet Visibility enables oversight of users and devices, supporting broader governance across the health system.
With its ability to work across departments and ultrasound devices, Compass AI provides health systems with the visibility, governance and standardization needed to expand POCUS at scale. The platform supports improved documentation accuracy, stronger compliance, streamlined QA processes and enhanced revenue capture from exams that previously went unbilled. Butterfly Network confirmed that Compass AI is available starting today.
BFLY’s Zacks Rank & Key Picks
Currently, BFLY carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Medpace Holdings (MEDP - Free Report) , Intuitive Surgical (ISRG - Free Report) and Boston Scientific (BSX - Free Report) .
Medpace, currently sporting a Zacks Rank #1 (Strong Buy), reported a third-quarter 2025 EPS of $3.86, which surpassed the Zacks Consensus Estimate by 10.29%. Revenues of $659.9 million beat the Zacks Consensus Estimate by 3.04%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MEDP has an estimated earnings growth rate of 17.1% for 2025 compared with the industry’s 16.6% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 14.28%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, posted a third-quarter 2025 adjusted EPS of $2.40, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $2.51 billion topped the Zacks Consensus Estimate by 3.9%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 11.9% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.34%.
Boston Scientific, currently carrying a Zacks Rank #2, reported a third-quarter 2025 adjusted EPS of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outperformed the Zacks Consensus Estimate by 1.9%.
BSX has an estimated long-term earnings growth rate of 16.4% compared with the industry’s 13.5% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.36%.